Block listing Interim Return REPLACEMENT

Avacta Group PLC

26 April 2024

 

 

 

The following amendment has been made to the publication of Block Listing Six Monthly Return released on 26/04/24 at 7:00AM under RNS No 1211M.  

The figure in the first table under "Equals: Balance under scheme(s) not yet issued/allotted at end of period" is 803,006, not 911,730 as announced.

The figure in the second table under "Equals: Balance under scheme(s) not yet issued/allotted at end of period" is 9,719,257, not 11,777,257 as announced.

All other details remain unchanged.  

The full amended text is shown below.

26 April 2024

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Block Listing Six Monthly Return

Avacta Group plc (AIM: AVCT), a life sciences developing innovative, targeted oncology drugs and powerful diagnostics, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:		Avacta Group plc
Name of scheme:		EMI scheme
Period of return:	From:	28 October 2023		27 April 2024
Balance of unallotted securities under scheme(s) from previous return:		797,922
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		113,808
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		108,724
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		803,006

Name of applicant:		Avacta Group plc
Name of scheme:		LTIP scheme
Period of return:	From:	28 October 2023		27 April 2024
Balance of unallotted securities under scheme(s):		5,277,257
Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		6,500,000
Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		2,058,000
Equals:   Balance under scheme(s) not yet issued/allotted at end of period:		9,719,257

Name of contact:	Tony Gardiner, Company Secretary
Telephone number of contact:	+ 44 (0) 1904 217070

Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director	Tel: [phone] www.avacta.com
Stifel Nicolaus Europe Limited (Nomad and Joint Corporate Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good	Tel: [phone] www.stifel.com
Peel Hunt (Joint Corporate Broker) James Steel / Chris Golden / Patrick Birkholm	Tel: [phone] www.peelhunt.com
ICR Consilium (Media and IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji	[e-mail]

About Avacta Group plc - https://www.avacta.com

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

Avacta has two divisions focused on therapeutics and diagnostics.

Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.

Avacta Diagnostics: focused on supporting healthcare professionals and broadening access to diagnostics.

Avacta has two proprietary platforms, pre|CISION™ and Affimer®.

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.

To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/

 

END